These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19491328)

  • 1. Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure.
    Dorn GW; Liggett SB
    Mol Pharmacol; 2009 Sep; 76(3):466-80. PubMed ID: 19491328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.
    Liggett SB; Mialet-Perez J; Thaneemit-Chen S; Weber SA; Greene SM; Hodne D; Nelson B; Morrison J; Domanski MJ; Wagoner LE; Abraham WT; Anderson JL; Carlquist JF; Krause-Steinrauf HJ; Lazzeroni LC; Port JD; Lavori PW; Bristow MR
    Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11288-93. PubMed ID: 16844790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure.
    Liggett SB; Cresci S; Kelly RJ; Syed FM; Matkovich SJ; Hahn HS; Diwan A; Martini JS; Sparks L; Parekh RR; Spertus JA; Koch WJ; Kardia SL; Dorn GW
    Nat Med; 2008 May; 14(5):510-7. PubMed ID: 18425130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure.
    Liggett SB
    Heart Fail Clin; 2010 Jan; 6(1):27-33. PubMed ID: 19945058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-blocker pharmacogenetics in heart failure.
    Shin J; Johnson JA
    Heart Fail Rev; 2010 May; 15(3):187-96. PubMed ID: 18437562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans.
    Kurnik D; Cunningham AJ; Sofowora GG; Kohli U; Li C; Friedman EA; Muszkat M; Menon UB; Wood AJ; Stein CM
    Pharmacogenomics; 2009 Oct; 10(10):1581-7. PubMed ID: 19842931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of beta1-adrenergic receptors in heart failure and hypertension.
    Mialet-Perez J; Liggett SB
    Arch Mal Coeur Vaiss; 2006 Jun; 99(6):616-20. PubMed ID: 16878723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics of beta-adrenergic receptors and their accessory signaling proteins in heart failure.
    Dorn GW; Liggett SB
    Clin Transl Sci; 2008 Dec; 1(3):255-62. PubMed ID: 20443857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes.
    Parikh KS; Fiuzat M; Davis G; Neely M; Blain-Nelson P; Whellan DJ; Abraham WT; Adams KF; Felker GM; Liggett SB; O'Connor CM; Bristow MR
    Circ Genom Precis Med; 2018 Aug; 11(8):e002210. PubMed ID: 30354340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study.
    Lee HY; Chung WJ; Jeon HK; Seo HS; Choi DJ; Jeon ES; Kim JJ; Shin JH; Kang SM; Lim SC; Baek SH
    Korean J Intern Med; 2016 Mar; 31(2):277-87. PubMed ID: 26879662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic factors affecting β-blocker metabolism and response.
    Thomas CD; Johnson JA
    Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):953-964. PubMed ID: 32726152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms present in G-protein-coupled receptor kinases and their effect on β-blocker treatment.
    Raake PW; Koch WJ; Most P
    Pharmacogenomics; 2011 Mar; 12(3):295-7. PubMed ID: 21449665
    [No Abstract]   [Full Text] [Related]  

  • 13. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
    Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
    Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure.
    Aleong RG; Sauer WH; Robertson AD; Liggett SB; Bristow MR
    Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):137-43. PubMed ID: 23275278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions.
    Johnson JA; Liggett SB
    Clin Pharmacol Ther; 2011 Mar; 89(3):366-78. PubMed ID: 21289619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-blockers in congestive heart failure: the pharmacology of carvedilol, a vasodilating beta-blocker and antioxidant, and its therapeutic utility in congestive heart failure.
    Feuerstein G; Ruffolo RR
    Adv Pharmacol; 1998; 42():611-5. PubMed ID: 9327976
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacogenomics of heart failure: a systematic review.
    Mottet F; Vardeny O; de Denus S
    Pharmacogenomics; 2016 Nov; 17(16):1817-1858. PubMed ID: 27813451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure.
    Mialet Perez J; Rathz DA; Petrashevskaya NN; Hahn HS; Wagoner LE; Schwartz A; Dorn GW; Liggett SB
    Nat Med; 2003 Oct; 9(10):1300-5. PubMed ID: 14502278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy.
    Terra SG; Hamilton KK; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hill JA; Aranda JM; Yarandi HN; Johnson JA
    Pharmacogenet Genomics; 2005 Apr; 15(4):227-34. PubMed ID: 15864115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure.
    Kang S; Hong X; Ruan CW; Yu P; Yu SS; Chen M; Zhang DF; Fan HM; Liu ZM
    J Transl Med; 2015 Feb; 13():44. PubMed ID: 25638254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.